Cholangiocarcinoma market survey report: by type (intrahepatic, extrahepatic), diagnosis (blood test, abdominal surgery), by treatment (analysis, placement therapy), to end users (hospitals and clinics, academic institutions)-to Forecast for 2027
Free sample 2 @https://www.marketresearchfuture.com/sample_request/4741
Cholangiocarcinoma, a rare type of tumor, has mutations in the bile duct epithelial cells and shows epithelial differentiation. According to data from the National Cancer Institute, in 2014, there were an estimated 66,771 cases of intrahepatic cholangiocarcinoma in the United States. It is estimated that by the end of 2017, the disease will cause 28,920 deaths, accounting for 4.8% of all cancer deaths. From 2005 to 2014, the death rate increased by 2.6% per year. This increasing prevalence of cholangiocarcinoma will drive the market during the forecast period. With the continuous growth of medical and health care, the understanding of diseases and the investors of treatment program developers are promoting the market. However, the high cost of treatment and related side effects in developing economies and low health care expenditures are expected to dampen the market during the forecast period.
Minute
The global cholangiocarcinoma market is segmented according to category, diagnosis, and treatment end users.
According to the category, the market is divided into intrahepatic and extrahepatic.
On the basis of diagnosis, the market is divided into blood test, abdominal imaging, surgery and so on. Diagnosis by the abdomen is divided into endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangography (PTC), magnetic resonance cholangiopancreatography (MRCP) and so on.
The basis of treatment, the market is divided into chemotherapy, placement therapy and so on. Chemotherapy is subdivided into 5-fluorouracil, gemcitabine, cisplatin and so on.
On the basis of end users, the market is segmented into hospitals and clinics, academic institutions, research institutions, etc.
Regional Analysis
The Americas dominate the global cholangiocarcinoma market due to the developed healthcare sector. Since then, more and more medical and health care branches have promoted the growth of the American market. According to data from the Centers for Disease Control and Prevention in the United States, the U.S. health care support in 2015. Reached 3.2 trillion US dollars, 990 US dollars, accounting for 17.8% of the total GDP. In addition, global market leaders such as Pfizer and Bristol-Myers Squibb in the region have pushed for market growth during the forecast period.
Main participant
A major player in the global cholangiocarcinoma market, Pfizer (U.S.), F. Hoffman-La Roche Co., Ltd. (Europe), Bristol-Myers Squibb (U.S.), Teva Pharmaceutical Industry Co., Ltd. (Middle East)
Eli Lilly and Company. (United States), Sanofi (Europe), Fresenius Kabi AG (Europe), Mylan NV (United States).
Access the report https://www.marketresearchfuture.com/reports/bile-duct-cancer-market-4741
Regarding market governance in the future.
At Market Research Future (MRFR), we use our cooked food report (CRR), half-cooked treatment report (HCRR), statistical report continuous feed treatment (CFR) and market management consulting services, so that our customers can solve the complexities of various industries.
